文献速递肾小球疾病急性肾损伤

ANCA与抗GBM双阳性患者的肾脏生存、复发频率及结局多样

Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients.
PubMed 文献 · Kidney Int · 2017-05-12

该研究回顾性分析欧洲四中心568例ANCA相关血管炎、41例抗GBM病及37例双阳性患者,发现双阳性患者兼具两病特征,肾脏生存介于单阳性组之间,患者生存三组相似,但双阳性及AAV组约半数复发,而抗GBM单阳性无复发。

要点

  • 双阳性患者兼具AAV与抗GBM病特征,需早期积极治疗抗GBM病。
  • 双阳性患者长期肾脏生存介于单阳性组之间,但患者生存三组相似。
  • 双阳性及AAV患者约半数复发,需长期随访并考虑维持免疫抑制。

核心结论

  • 双阳性患者具有混合疾病表型,需兼顾抗GBM病的积极早期治疗与AAV的长期维持免疫抑制。

研究设计与样本

  • 回顾性分析欧洲四中心568例ANCA相关血管炎、41例抗GBM病及37例双阳性患者的临床特征与长期结局。

主要发现

  • 双阳性患者年龄分布较老、诊断前症状持续时间较长,且就诊时肾病严重、肺出血频率高。
  • 双阳性患者肾活检慢性损伤证据多于抗GBM病患者,但治疗后脱离透析倾向更大,长期肾脏生存介于单阳性组之间。
  • 三组患者总体生存相似,不良生存预测因素包括高龄、严重肾衰竭和就诊时肺出血。
  • 中位随访4.8年期间,抗GBM单阳性患者无复发,而AAV和双阳性存活患者约半数复发。

临床怎么用

  • 对双阳性患者应早期积极治疗抗GBM病,并长期随访、考虑维持免疫抑制以预防AAV复发。

局限性

  • 回顾性研究,双阳性样本量较小(37例),来自四个中心,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Co-presentation with both ANCA and anti-GBM antibodies is thought to be relatively rare. Current studies of such 'double-positive' cases report small numbers and variable outcomes. To study this further we retrospectively analyzed clinical features and long-term outcomes of a large cohort of 568 contemporary patients with ANCA-associated vasculitis, 41 patients with anti-GBM disease, and 37 double-positive patients with ANCA and anti-GBM disease from four European centers. Double-positive patients shared characteristics of ANCA-associated vasculitis (AAV), such as older age distribution and longer symptom duration before diagnosis, and features of anti-GBM disease, such as severe renal disease and high frequency of lung hemorrhage at presentation. Despite having more evidence of chronic injury on renal biopsy compared to patients with anti-GBM disease, double-positive patients had a greater tendency to recover from being dialysis-dependent after treatment and had intermediate long-term renal survival compared to the single-positive patients. However, overall patient survival was similar in all three groups. Predictors of poor patient survival included advanced age, severe renal failure, and lung hemorrhage at presentation. No single-positive anti-GBM patients experienced disease relapse, whereas approximately half of surviving patients with AAV and double-positive patients had recurrent disease during a median follow-up of 4.8 years. Thus, double-positive patients have a truly hybrid disease phenotype, requiring aggressive early treatment for anti-GBM disease, and careful long-term follow-up and consideration for maintenance immunosuppression for AAV. Since double-positivity appears common, further work is required to define the underlying mechanisms of this association and define optimum treatment strategies.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. McAdoo SP, Tanna A, Hrušková Z, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int. 2017. PMID: 28506760. doi:10.1016/j.kint.2017.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。